Antiviral abzyme

外国特許コード	F170009201
整理番号	AF12-05WO
掲載日	2017年9月12日
出願国	欧州特許庁（ＥＰＯ）
出願番号	11744803
公報番号	2537931
公報番号	2537931
出願日	平成23年2月21日(2011.2.21)
公報発行日	平成24年12月26日(2012.12.26)
公報発行日	平成28年10月19日(2016.10.19)
国際出願番号	JP2011053752
国際公開番号	WO2011102517
国際出願日	平成23年2月21日(2011.2.21)
国際公開日	平成23年8月25日(2011.8.25)
優先権データ	特願2010-034998 (2010.2.19) JP 特願2010-035021 (2010.2.19) JP 特願2010-092461 (2010.4.13) JP 2011WO-JP53752 (2011.2.21) WO
発明の名称 （英語）	Antiviral abzyme
発明の概要（英語）	(EP2537931) The present invention provides: a novel antiviral agent containing a human antibody º light chain, a novel human abzyme containing a human antibody º light chain; a polynucleotide, a vector, and a transformant, each of which relating to the containing a human antibody º light chain of the above; a primer set for effectively obtaining a human antibody º light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set.
特許請求の範囲（英語）	[claim1] 1. An antiviral agent comprising a human antibody kappa light chain consisted of a polypeptide having a variable domain represented by the amino acid sequence shown in SEQ ID NO: 14, 26, 22, 30, 50, 54, or 35. [claim2] 2. The antiviral agent as set forth in claim 1, wherein the human antibody kappa light chain is a monomer. [claim3] 3. The antiviral agent as set forth in claim 2, wherein the amino acid sequence of the human antibody kappa light chain is modified such that cysteine forming a disulfide bonding with another light chain is deleted or substituted with another amino acid than cysteine. [claim4] 4. The antiviral agent as set forth in claim 3, wherein the human antibody kappa light chain consists of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 15, 27, 31, 51, 55, or 36. [claim5] 5. The antiviral agent as set forth in any one of claims 1 to 4, wherein the virus is an minus single-strand RNA virus. [claim6] 6. The antiviral agent as set forth in any one of claims 1 to 5, wherein: the variable domain consists of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 14, 26, 22 or 30; and the virus is a virus belonging to Rhabdoviridae. [claim7] 7. The antiviral agent as set forth in any one of claims 1 to 5, wherein: the variable domain consists of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 14, 26, 50, 54 or 35; and the virus is an influenza virus. [claim8] 8. A human abzyme being a human antibody kappa light chain against rabies virus and having an amidase activity and a variable domain consisting of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 14, 26, 16, 18, 30, 35, or 40. [claim9] 9. A human abzyme being a human antibody kappa light chain against rabies virus and having a nucleolytic activity and a variable domain consisting of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 14, 26, 30, 50, or 54. [claim10] 10. A human abzyme being a human antibody kappa light chain against rabies virus and cytotoxic to cancer cells, and having a variable domain consisting of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 14, or 30. [claim11] 11. A human abzyme being a human antibody kappa light chain against rabies virus and having an anti virus activity and a variable domain consisting of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 14, 26, 22, 30, 50, 54, or 35. [claim12] 12. The human abzyme as set forth in any one of claims 8 to 11, wherein the human antibody kappa light chain is such that cysteine for forming a disulfide bond with another light chain is deleted or substituted with an amino acid or amino acids other than cysteine. [claim13] 13. The human abzyme as set forth in claim 12, wherein the kappa light chain consists of a polypeptide represented by the amino acid sequence shown in SEQ ID NO: 15, 27, 17, 19, 31, 36, 41, 23, 51, or 55. [claim14] 14. A polynucleotide for encoding the human antibody kappa light chain recited in any one of claims 1 to 13. [claim15] 15. A vector containing a polynucleotide as set forth in claim 14. [claim16] 16. A transformant in which a polynucleotide as set forth in claim 14 is introduced. [claim17] 17. A primer set for amplifying a polynucleotide for encoding at least a variable domain of a human antibody kappa light chain via two-stage PCR reaction using a human cDNA as a template, comprising: a first primer for first-stage PCR reaction, the first primer being a polynucleotide having a domain hybridizable with the template in the first stage PCR reaction, the domain being represented by the nucleotide sequence shown in SEQ ID NO: 43 or 44. [claim18] 18. The primer set as set forth in claim 17, comprising: a second primer for second-stage PCR reaction, the second primer being a polynucleotide hybridizable specifically with a polynucleotide represented by a complementary sequence for the nucleotide sequence shown in SEQ ID NO: 45. [claim19] 19. A primer set for amplifying a polynucleotide for encoding at least a variable domain of a human antibody kappa light chain via two-stage PCR reaction using a human cDNA as a template, comprising: a first primer for first-stage PCR reaction, the first primer being a polynucleotide hybridizable specifically with a poly nucleotide represented by a complementary sequence for the nucleotide sequence shown in SEQ ID NO: 43 or 44; and a second primer for second-stage PCR reaction, the second primer being a polynucleotide hybridizable specifically with a poly nucleotide represented by a complementary sequence for the nucleotide sequence shown in SEQ ID NO: 45. [claim20] 20. The primer set as set forth in any one of claims 17 to 19, further comprising: a third primer for the first-stage PCR reaction, the third primer being a polynucleotide hybridizable specifically with part of a gene sequence of a constant domain of the human antibody kappa type light chain; and a fourth primer for the second-stage PCR reaction, the fourth primer being a polynucleotide hybridizable specifically with part of the gene sequence of the constant domain of the human antibody kappa type light chain. [claim21] 21. The primer as set forth in claim 20, wherein: the third primer is a polynucleotide hybridizable specifically with a polynucleotide represented by a complementary sequence for the nucleotide sequence shown in SEQ ID NO: 46; and the fourth primer is the polynucleotide hybridizable specifically with the polynucleotide represented by the complementary sequence for the nucleotide sequence shown in SEQ ID NO: 46. [claim22] 22. The primer set as set forth in any one of claims 17 to 21, wherein the human cDNA is derived from a lymph cell. [claim23] 23. A method for producing a polynucleotide, the method comprising: performing two-stage PCR reaction by using a primer set as set forth in any one of claims 17 to 22, so as to amplify the polynucleotide for encoding at least the variable domain of the human antibody kappa light chain from human cDNA. [claim24] 24. A method for producing a polypeptide, the method comprising: producing a polynucleotide by a method as set forth in claim 23; and expressing the polynucleotide inside a host cell.
出願人（英語）	JAPAN SCIENCE AND TECHNOLOGY AGENCY
発明者（英語）	UDA TAIZO HIFUMI EMI NISHIZONO AKIRA ARAKAWA MITSUE
国際特許分類(IPC)	A61K  39/00      抗原または抗体を含有する医薬品製剤 A61K  39/395     抗体；免疫グロブリン；免疫血清，例．抗リンパ球血清 C07K  16/10      ＲＮＡウイルスから C12N   9/00      酵素，例．リガーゼ；酵素前駆体；その組成物；酵素の調製，活性化，阻害，分離または精製方法 C12N  15/09      組換えＤＮＡ技術 C12P  21/08      モノクローナル抗体
指定国	(EP2537931) Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
参考情報 （研究プロジェクト等）	CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA